L
2.58
0.04 (1.57%)
| Penutupan Terdahulu | 2.54 |
| Jumlah Dagangan | 266,407 |
| Harga / Buku (P/B) | 3.15 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.51 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.37% |
| Nisbah Semasa (MRQ) | 7.48 |
| Aliran Tunai Operasi (OCF TTM) | -86.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.86 M |
| Pulangan Atas Aset (ROA TTM) | -31.47% |
| Pulangan Atas Ekuiti (ROE TTM) | -50.77% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Larimar Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
0.3
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -4.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| Persekitaran Makro | -0.3 |
| AI Insight | NA |
| Purata | 0.31 |
|
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.43% |
| % Dimiliki oleh Institusi | 103.11% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Blue Owl Capital Holdings Lp | 30 Jun 2026 | 9,163,157 |
| Defilade Capital Management, L.P. | 30 Jun 2026 | 3,670,135 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |